Prolonged-release oxycodone-naloxone for pain management in advanced EGFR wild-type lung cancer patients

被引：1
|
作者：
Stella, Giulia M. [1 ]
Piloni, Davide [2 ]
Ciuffreda, Antonio [1 ]
Spiaggi, Ernestina [1 ]
Marino, Elisa [1 ]
Ilardi, Marcella [3 ]
Cavalloro, Fabrizio [3 ]
机构：
[1] San Matteo Polyclin & Inst Res & Care, Sect Pneumol, Dept Cardiothorac Surg, I-27100 Pavia, Italy
[2] Univ Pavia, Dept Internal Med, Unit Pneumol, Pavia, Italy
[3] San Matteo Polyclin & Inst Res & Care, Emergency Dept, Pain Unit, Pavia, Italy
来源：
MINERVA MEDICA | 2018年 / 109卷 / 04期
关键词：
D O I：
10.23736/S0026-4806.18.05287-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：337 / 340
页数：5
相关论文
共 50 条
  • [31] A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR
    Dupoiron, D.
    Stachowiak, A.
    Loewenstein, O.
    Ellery, A.
    Kremers, W.
    Bosse, B.
    Hopp, M.
    EUROPEAN JOURNAL OF PAIN, 2017, 21 (09) : 1528 - 1537
  • [32] Clinical Study on Fluvoxamine Combined with Oxycodone Prolonged-Release Tablets in Treating Patients with Moderate to Severe Cancer Pain
    Xiao, Yang
    Liu, Jun
    Huang, Xin-En
    Ca, Li-Hua
    Ma, Yi-Min
    Wei, Wei
    Zhang, Rong-Xia
    Huang, Xiao-Hong
    Chang, Juan
    Wu, Yi-Jia
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (23) : 10445 - 10449
  • [33] High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain
    Francesco Amato
    Silvia Ceniti
    Sergio Mameli
    Giovanni M. Pisanu
    Renato Vellucci
    Vincenzo Palmieri
    Leonardo Consoletti
    Dorotea Magaldi
    Paolo Notaro
    Claudio Marcassa
    Supportive Care in Cancer, 2017, 25 : 3051 - 3058
  • [34] High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain
    Amato, Francesco
    Ceniti, Silvia
    Mameli, Sergio
    Pisanu, Giovanni M.
    Vellucci, Renato
    Palmieri, Vincenzo
    Consoletti, Leonardo
    Magaldi, Dorotea
    Notaro, Paolo
    Marcassa, Claudio
    SUPPORTIVE CARE IN CANCER, 2017, 25 (10) : 3051 - 3058
  • [35] EGFR endocytosis is a rational target in lung cancer with wild-type EGFR
    Jo, Ukhyun
    Park, Kyong Hwa
    Whang, Young M.
    Sung, Jae Sook
    Won, Nam Hee
    Park, Jong Kuk
    Kim, Yeul Hong
    CANCER RESEARCH, 2014, 74 (19)
  • [36] Optimisation of EGFR TKI efficiency wild-type EGFR lung cancer
    Raimbourg, Judith
    Cabart, Mathilde
    Joalland, Marie-Pierre
    Decaudin, Didier
    Deplater, Ludmilla
    Lanoe, Didier
    Douillard, Jean-Yves
    Bennouna, Jaafar
    Vallette, Francois
    Lalier, Lisenn
    CANCER RESEARCH, 2015, 75
  • [37] Efficacy and safety of oral Morphine versus oral Prolonged-Release Oxycodone/Naloxone in opioid-naive cancer patients: a propensity analysis
    Greco, M. T.
    Roberto, A.
    Legramandi, L.
    Galli, F.
    Corli, O.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice
    Schutter, U.
    Grunert, S.
    Meyer, C.
    Schmidt, T.
    Nolte, T.
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (06) : 1377 - 1387
  • [39] EGFR tyrosine kinase inhibitor in advanced non-small cell lung cancer with wild-type EGFR
    Wang, Z.
    Wu, Y. L.
    Yang, J.
    Wang, B.
    Huang, Y.
    Zhou, Q.
    Xu, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Impact of Prolonged-release Oxycodone/Naloxone on Outcomes Affecting Patients' Daily Functioning in Comparison With Extended-release Tapentadol: A Systematic Review
    Thakur, Deepika
    Dickerson, Sara
    Bhutani, Mohit Kumar
    Junor, Rod
    CLINICAL THERAPEUTICS, 2015, 37 (01) : 212 - 224
12345